Fig. 2. Validation and characterization of selected antibodies.
a, ELISA area under the curve (AUC) values for binding to SARS-CoV-2 recombinant antigen proteins and a negative control influenza hemagglutinin protein are shown for antibodies (rows) in each experiment and were calculated from data in Extended Data Fig. 2b. b, Kd (M) values of antibodies for SARS-CoV-2 RBD or NTD (based on epitope shown in a) were determined by biolayer interferometry; ND, not done. c, Percent reduction in ACE2 binding, as measured by ELISA, is shown as a heat map from 0 to 100% (white to blue) reduction in binding compared to SARS-CoV-2 binding only. d, Vesicular stomatitis virus (VSV)–SARS-CoV-2 neutralization half-maximum inhibitory concentration (IC50) values are shown as a heat map from high potency (red) to low potency (green). Non-neutralizing antibodies are shown as white.